CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy

Gliomas are very malignant brain tumors that difficult to treat. CD47 is an antiphagocytic molecule binds SIPRα on phagocytes. It overexpressed the plasma membranes of multiple human tumor cell types and important diagnostic prognostic biomarker in many cancer. However, association between protein expression glioma tissue clinicopathological stage has not been investigated detail. A total 80 surgical specimens were stained with anti-CD47 antibody assess relationship glioma. Wound healing assays performed analyze influence migration invasion cells, near-infrared fluorescence localization a U-87 MG-bearing xenograft model used determine distribution vivo. MTT administration U251-bearing inhibitory effects gliomas. was higher high-grade gliomas than low-grade gliomas, high positively correlated histology stage. over-expression promoted growth motility two lines (U-87 MG U251) laboratory-developed accumulated at site. Proliferation U251 cells significantly inhibited by vitro, but also enhanced inhibition capacity Taxol. Our results suggest plays critical role progression from I IV may be potential target for treatment appears play prepared laboratory inhibit